Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price ▲ | Potential |
|---|---|---|---|---|---|---|---|
| Ipsen S.A. | 1 | 0 | 0 | 0 | €112.50 | €109.00 | -3.111% |
| Novartis AG ADR | 5 | 1 | 3 | 1 | €99.80 | €110.00 | 10.220% |
| Abbott Laboratories | 20 | 0 | 2 | 0 | €94.66 | €115.65 | 22.173% |
| Merck & Co. Inc. | 34 | 1 | 6 | 0 | €116.00 | €125.34 | 8.050% |
| Neurocrine Bioscience | 33 | 0 | 2 | 0 | €127.00 | €140.87 | 10.919% |
| Ascendis Ph.sp.adr 1 Dk 1 | 1 | 0 | 0 | 0 | €125.00 | €150.00 | 20.000% |
| Novo Nordisk A/S ADR | 40 | 1 | 24 | 0 | €131.00 | €150.00 | 14.504% |
| AstraZeneca plc | 2 | 0 | 0 | 0 | €143.15 | €165.00 | 15.264% |
| Novo Nordisk A/S | 4 | 0 | 0 | 0 | €185.00 | €172.50 | -6.757% |
| AbbVie Inc. | 43 | 0 | 22 | 0 | €151.92 | €176.30 | 16.049% |
| Johnson & Johnson | 42 | 1 | 9 | 0 | €134.80 | €179.00 | 32.789% |
| Krystal Biotech | 17 | 0 | 0 | 0 | €166.00 | €180.00 | 8.434% |
| Sarepta Therapeutics | 9 | 0 | 8 | 0 | €141.35 | €185.00 | 30.881% |
| Zoetis Inc. A | 23 | 1 | 0 | 0 | €162.02 | €200.06 | 23.477% |
| Charles River Labs Intl | 11 | 0 | 1 | 0 | €186.45 | €249.59 | 33.865% |
| Genmab A/S | 1 | 0 | 1 | 0 | €236.20 | €250.00 | 5.843% |
| Alnylam Pharmace. | 47 | 0 | 11 | 0 | €227.00 | €251.80 | 10.926% |
| United Therapeutics | 21 | 0 | 2 | 0 | €287.90 | €288.66 | 0.264% |
| Biogen Inc. | 57 | 1 | 8 | 0 | €205.30 | €291.49 | 41.984% |
| Amgen Inc. | 33 | 0 | 9 | 0 | €284.50 | €304.82 | 7.142% |
| Madrigal Pharmaceuticals inc. | 4 | 0 | 1 | 0 | €248.90 | €320.00 | 28.566% |
| Icon plc | 21 | 0 | 1 | 0 | €292.20 | €324.79 | 11.153% |
| Medpace Holdings Inc | 12 | 0 | 1 | 0 | €373.00 | €419.82 | 12.552% |
| Vertex Pharmaceuticals Inc. | 55 | 2 | 8 | 0 | €431.00 | €436.84 | 1.354% |
| Eli Lilly Corp. | 78 | 0 | 30 | 0 | €831.70 | €895.00 | 7.611% |